结核流行区局部晚期NSCLC的PET-CT纵隔过度分期:SUV阈值重校准改善PET/EBUS一致性
在结核流行中低收入国家,52例IIIA-C期NSCLC患者的回顾性盲法一致性研究显示,PET-CT再解读与EBUS-TBNA细胞学在纵隔淋巴结分期上的一致性仅为一般(κ=0.26),PET阳性而EBUS阴性者达18例。探索性应用SUVmax≥5.8阈值可将κ提升至0.43、特异度从36%升至61%,但多数PET阳性而未获病理确认的淋巴结站仍被纳入放疗靶区。
要点
- 结核流行区局部晚期NSCLC中,PET-CT对纵隔淋巴结存在系统性过度分期。
- 探索性SUVmax≥5.8阈值可改善患者层面PET/EBUS一致性及特异度。
- 多数PET阳性但细胞学阴性或未取样的淋巴结站仍被纳入放疗靶区。
核心结论
- 在结核流行队列中,PET系统性过度分期纵隔病变,且PET阳性而非组织学确认驱动了放疗靶区设计。
- 探索性SUVmax阈值≥5.8大幅改善患者层面一致性,尚需进一步验证。
研究设计与样本
- 回顾性、单中心、盲法一致性研究,连续纳入52例IIIA-C期NSCLC患者。
- 由一名核医学医师在不知晓全部临床数据的情况下重新解读去标识化PET-CT图像。
- 患者层面一致性(任何N2/N3受累)采用Cohen's κ和McNemar检验评估。
- 在75个PET可见且经EBUS取样的淋巴结站中,用ROC评估SUVmax的判别效能。
主要发现
- 患者层面一致性为一般(κ=0.26;95%CI:0.04-0.48),不一致呈强方向性:PET+/EBUS-者18例,PET-/EBUS+者2例(p<0.001)。
- PET-CT再解读的特异度为36%。
- 在取样淋巴结站中,确认恶性淋巴结的SUVmax高于假阳性(中位8.8 vs. 5.4;p=0.002;AUC 0.76)。
- 将源自N2的阈值≥5.8应用于患者层面分类后,9例患者被重新分类,κ从0.26(一般)提升至0.43(中等),特异度从36%提升至61%。
- 尽管细胞学阴性或未取样,71%的假阳性淋巴结站和84%的未取样PET阳性淋巴结站仍被纳入放疗临床靶区。
关键数值与推荐
- 患者层面一致性κ=0.26(95%CI:0.04-0.48)。
- 确认恶性与假阳性淋巴结站SUVmax中位8.8 vs. 5.4(p=0.002;AUC 0.76)。
- 探索性SUVmax阈值≥5.8使κ从0.26升至0.43,特异度从36%升至61%。
- 71%的假阳性和84%的未取样PET阳性淋巴结站被纳入放疗临床靶区。
临床怎么用
- 在结核流行区进行局部晚期NSCLC纵隔分期时,应警惕PET-CT过度分期,PET阳性结果需经EBUS-TBNA组织学确认。
- 放疗靶区设计不应仅依据PET阳性,应结合病理取材结果,避免将未确认的PET阳性淋巴结站常规纳入。
- 探索性SUVmax≥5.8阈值可作为改善PET/EBUS一致性的参考,但需进一步验证后方可用于临床决策。
局限性
- 回顾性、单中心研究,样本量为52例连续患者。
- SUVmax≥5.8阈值为探索性分析,需进一步验证。
- 仅由一名核医学医师进行盲法再解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To quantify concordance between blinded PET-CT reinterpretation and EBUS-guided transbronchial needle aspiration (EBUS-TBNA) cytology for mediastinal lymph node staging in locally advanced NSCLC in a tuberculosis-endemic lower-middle income country (LMIC). METHODS: Retrospective, single-institution blinded concordance study of 52 consecutive Stage IIIA-C NSCLC patients. A nuclear medicine physician, blinded to all clinical data, reinterpreted deidentified PET-CT images. Patient-level agreement (any N2/N3 involvement) was assessed using Cohen's κ and McNemar's test. Among 75 PET-visible EBUS-sampled stations, SUVmax discriminative performance was evaluated by ROC. Candidate thresholds were applied to the patient-level classification to assess performance. Inclusion of nodal stations into radiotherapy volumes was also assessed. RESULTS: Patient-level agreement was fair (κ = 0.26; 95% CI: 0.04-0.48) with strongly directional discordance: 18 patients were PET+/EBUS- versus 2 PET-/EBUS+ (p < 0.001). PET-CT re-read specificity was 36%. Among sampled stations, confirmed malignant nodes had higher SUVmax than false-positives (median 8.8 vs. 5.4; p = 0.002; AUC 0.76). Applying the N2-derived threshold of ≥ 5.8 to patient-level classification reclassified 9 patients, improving κ from 0.26 (fair) to 0.43 (moderate) and specificity from 36% to 61%. Despite negative or absent cytology, 71% of false-positive and 84% of unsampled PET-positive stations were included in the radiotherapy clinical target volume. CONCLUSION: In this TB-endemic cohort, PET systematically over-staged mediastinal disease, and PET positivity rather than tissue confirmation drove radiation volume design. An exploratory SUVmax threshold of ≥ 5.8 substantially improved patient-level concordance and needs further validation.
引用
- Gupta M, Ahmad I, Chufal KS, et al. Mediastinal over-staging with PET-CT in tuberculosis-endemic locally advanced NSCLC: SUV threshold recalibration improves PET/EBUS concordance. Eur J Nucl Med Mol Imaging. 2026. PMID: 42249940. doi:10.1007/s00259-026-07979-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。